



20 JUN 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

AA
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Tom Hunter
Quine Intellectual Property Law Group, P.C.
P.O. Box 458
Alameda, CA 94501

In re Application of
FOGELMAN, et al.
U.S. Application No.: 10/520,207
PCT No.: PCT/US03/09988
Int. Filing Date: 01 April 2003
Priority Date: 02 April 2002
Attorney Docket No.: 407T-301110US
For: G-TYPE PEPTIDES TO AMELIORATE
ATHEROSCLEROSIS

DECISION ON PETITION

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 27 December 2004 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National fee and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being forwarded to the United States Designated/Elected Office (US/DO/EO) for continued processing including the issuance of a Notification of Missing Requirements (Form PCT/DO/EO/905) indicating that an executed oath or declaration of the inventors is required.

Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459